LIAN - LianBio gets approval for heart drug Camzyos in Macau

2023-05-11 08:06:38 ET

• LianBio ( NASDAQ: LIAN ) said Pharmaceutical Administration Bureau of the Macau approved Camzyos (mavacamten) to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the Macau Special Administrative Region (SAR) of China
• "Macau marks mavacamten’s first approval in LianBio's licensed territories," said LianBio CEO Yizhe Wang.
• The drug is also under priority review in China.
• LianBio licensed rights to mavacamten from MyoKardia, now a unit of Bristol Myers Squibb ( NYSE: BMY ).
• Bristol Myers' filing for Camzyos  is under review in the U.S. with a decision by the FDA expected by June 16. Meanwhile, the drug has inched closer to approval in the EU following greenlight from a panel of the European Medicines Agency in April.
• HCM is a condition in which the heart muscle becomes abnormally thick which can make it harder for the heart to pump blood.

For further details see: